🇺🇸 arginine/lysine in United States
213 US adverse-event reports
Safety signals — FAERS
Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.
- Window: 22 April 2025 – 22 April 2026
- Total reports: 213
Most-reported reactions
- Platelet Count Decreased — 40 reports (18.78%)
- Malignant Neoplasm Progression — 37 reports (17.37%)
- Anaemia — 28 reports (13.15%)
- Lymphocyte Count Decreased — 20 reports (9.39%)
- Inappropriate Schedule Of Product Administration — 19 reports (8.92%)
- White Blood Cell Count Decreased — 16 reports (7.51%)
- Decreased Appetite — 14 reports (6.57%)
- Nausea — 14 reports (6.57%)
- Diarrhoea — 13 reports (6.1%)
- Myelosuppression — 12 reports (5.63%)
arginine/lysine in other countries
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Other Immunology approved in United States
Frequently asked questions
Is arginine/lysine approved in United States?
arginine/lysine does not currently have US marketing authorisation in our dataset.
Who is the marketing authorisation holder for arginine/lysine in United States?
Advanced Accelerator Applications is the originator. The local marketing authorisation holder may differ — check the official source linked above.